A
Alnylam Pharmaceuticals, Inc. (ALNY)
NMS – Real Time Price. Currency in USD
292.03
+7.19 (2.52%)
At close: May 12, 2026, 4:00 PM EDT
290.27
-1.76 (-0.60%)
Pre-market: May 13, 2026, 7:52 AM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
292.03
+7.19 (2.52%)
At close: May 12, 2026, 4:00 PM EDT
290.27
-1.76 (-0.60%)
Pre-market: May 13, 2026, 7:52 AM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.13 | 6.05 | 10 | |
| Quick ratio | 3.06 | 5.63 | 10 | |
| Debt to Equity | 2.76 | 0.30 | 2.0 | |
| Debt to Assets | 0.58 | 1.04 | 4.0 | |
| Interest coverage | 3.88 | -16.91 | 9.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1.04B | 1.83B | 2.25B | 3.71B | 4.29B |
| Gross Profit | 869M | 1.52B | 1.92B | 3.03B | 3.46B |
| Operating Income | -785M | -282M | -177M | 502M | 752M |
| Net Income | -1.13B | -440M | -278M | 314M | 577M |
| EBITDA | -741M | -228M | -120M | 557M | 807M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 71.15 | 414.94 | 10 |
| Next quarter | 18.53 | 7.35 | 7.0 |
| Current year | 51.23 | 217.25 | 10 |
| Next year | 31.4 | 44.02 | 10 |
| Weighted average score | 9.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 6.39 | 10.5 | 84.15 | -65.29 | 5.8 |
| Y/Y | 96.43 | 1228.66 | 443.18 | 137.65 | 10 |
| 3y average | 54.8 | 103.56 | 102.37 | 366.01 | 10 |
| 5y average | 51.72 | 55.74 | 56.29 | 221.57 | 10 |
| Weighted average score | 9.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Medium | 7.0 |
| Intangible assets | Medium | 7.0 |
| Switching costs | Medium | 6.0 |
| Network effect | Medium | 6.0 |
| Economies of scale | Medium | 7.0 |
| Weighted average score | 6.6 | |
Total debt $3.0B significantly exceeds cash reserves ($1.7B), raising financial stability concerns
Total current assets $4.2B exceed Total current liabilities $1.3B, highlighting excellent liquidity
Debt-to-equity ratio (2.8) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (4x) indicates the company easily manages its debt payments
The company generates positive free cash flow $48.7M, supporting its financial health